Investigational drug · Phase 2
IBI305
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 15, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
93
Any phase or sponsor naming "IBI305"
First trial start
2025
Aug 31, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBI305", any sponsor or status.
Conditions studied
As listed on its trial records.
- EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "IBI305" as an intervention, largest first.
- Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT00433511 · 4,994 participants · Start Nov 2, 2007 · Primary completion Jan 7, 2014
Drug: Bevacizumab; Cyclophosphamide and 2 more · For: Breast Adenocarcinoma
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 842 sites in all
- Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00096278 · 2,710 participants · Start Sep 15, 2004 · Primary completion Mar 12, 2009
Drug: Bevacizumab; Fluorouracil and 2 more · For: Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v7; Stage IIB Colon Cancer AJCC v7 and 4 more
Sites: Pittsburgh, Pennsylvania
- Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00217737 · 2,431 participants · Start Sep 6, 2005 · Primary completion Feb 22, 2024
Drug: Bevacizumab; Fluorouracil and 2 more · For: Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v7; Stage IIB Colon Cancer AJCC v7 and 1 more
Sites: Anniston, Alabama; Birmingham, Alabama; Huntsville, Alabama · 928 sites in all
- Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00951496 · 1,560 participants · Start Aug 11, 2009 · Primary completion Jan 11, 2016
Drug: Bevacizumab; Carboplatin and 4 more · For: Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma and 35 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 503 sites in all
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By SurgeryPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00324805 · 1,501 participants · Start Jul 19, 2007 · Primary completion Oct 20, 2015
Drug: Bevacizumab; Cisplatin and 4 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 and 1 more
Sites: Anniston, Alabama; Huntsville, Alabama; Mobile, Alabama · 1,169 sites in all
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT00565851 · 1,052 participants · Start Dec 6, 2007 · Primary completion Apr 30, 2019
Drug: Bevacizumab; Carboplatin and 3 more · For: Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma and 22 more
Sites: Anchorage, Alaska; Hot Springs, Arkansas; Auburn, California · 709 sites in all
- Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerPivotal-lookingRecruiting
NRG OncologyAcademic, hospital or other
NCT06580314 · 880 participants (planned) · Start Mar 12, 2025 · Primary completion Dec 31, 2034
Drug: Bevacizumab; Olaparib · For: Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor and 9 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 709 sites in all
- Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00785291 · 799 participants · Start Oct 13, 2008 · Primary completion Dec 31, 2013
Drug: Bevacizumab; Ixabepilone and 2 more · For: Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative and 6 more
Sites: Scottsdale, Arizona; Fort Smith, Arkansas; Jonesboro, Arkansas · 704 sites in all
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT01167712 · 692 participants · Start Oct 12, 2010 · Primary completion Dec 1, 2015
Drug: Bevacizumab; Carboplatin and 1 more · For: Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma and 27 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 563 sites in all
- A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.Pivotal-lookingStatus unknown
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT03794440 · 595 participants · Start Feb 11, 2019 · Primary completion Dec 2022
Drug: Sintilimab; IBI305 and 1 more · For: Hepatocellular Carcinoma
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Dramatic and sustained regression of an inferior vena cava tumor thrombus in a patient with unresectable giant hepatocellular carcinoma following sequential systemic therapy: a case report and literature review.
Hou J, Wu KL · Front Oncol 2026
- Integrating multiple outcomes of first-line immunotherapy-based regimens for advanced hepatocellular carcinoma: A network meta-analysis of phase III trials.
Nie G, Li X, Wang Y, et al. · Crit Rev Oncol Hematol 2026
- Sintilimab plus Bevacizumab biosimilar IBI305 and chemotherapy as a first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single-arm, phase Ib/II study.
Cheng M, Zhang P, Hu Q, et al. · Nat Commun 2026
- A dual-level Bayesian network meta-analysis of first-line immunotherapy in advanced hepatocellular carcinoma: strategy-level and regimen-level evidence.
Zhang Q, Hu Y, Ge Y, et al. · Front Immunol 2026
- Efficacy of immune-based combinations across treatment lines in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
Zhao W, Wu Z, Qiao S, et al. · Front Pharmacol 2026
- Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD-1 Inhibitor Plus TKIs in Combination of TACE for uHCC.
Ya H, Wang K, Qin H, et al. · Liver Int 2026
Also in development for EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.